MedTech Valuation Multiples
Explore private market MedTech valuation multiples with benchmarks structured by stage and region. Updated quarterly.
MedTech
Medical Technology companies design and manufacture devices, diagnostics, and therapeutic systems that improve clinical care. Private market valuations reflect regulatory approval status, clinical adoption, reimbursement coverage, and the strength of IP protection in a capital-intensive development environment.
The category spans surgical robotics, imaging systems, point-of-care diagnostics, implantable devices, and digital surgery platforms. DealMatrix tracks valuation dynamics across 7 funding stages and all major global regions, updated every quarter.
Sector
MedTech
Health & Life Sciences
Sector tracked since
2000
25+ years of data
EV/SALES & EV/EBITDA ACROSS
6 Regions · 7 Stages
Modelled independently via proprietary econometric approach
UPDATE FREQUENCY
Quarterly
Data updates & model improvement
MedTech Valuation Multiples
Sector benchmark as of 31 March 2025 · median across 6 regions · updated quarterly
How we derive these multiples
DealMatrix multiples are derived from institutional-grade public-market index data covering ~150 GICS sub-industries across 6 regions, with quarterly history back to 2000. Regional scaling follows Damodaran (NYU Stern), and the methodology follows the IPEV Guidelines 2025. Published benchmarks are illustrative and dated; because IPEV 2025 prohibits static multiples for reporting periods from 1 April 2026, current quarterly data for valuation work is available on the platform.
The Venionaire DealMatrix Multiples Model
DealMatrix multiples are proprietary private-market benchmarks, derived through a six-step model that translates public capital-market index comparables into private-market segments and funding stages, adjusted for macroeconomic conditions.
The model produces three components: The reported public multiple, the model-predicted multiple, and the lower bound predicted multiple averaged into the DealMatrix Composite, then adjusted for region and funding stage. The methodology follows the IPEV Guidelines 2025.
Brainomix Completes £14M ($18M) Series C Round to Advance Its Transformative AI Imaging Technology in Healthcare
raised
Valuation
Audio health startup secures £12.4m from YFM
raised
Valuation
Region
Stage
“Size of a grain of rice”: Robeauté raises €27.2 million to transform neurosurgery with microrobots
raised
Valuation
CorFlow Therapeutics AG Completes €44 Million Series B Financing
raised
Valuation
Eurazeo Backs Moria’s Global Expansion Plans
raised
Valuation
Region
Stage
TRiCares Raises $50m in Series D Financing to Support Upcoming Clinical Milestones
raised
Valuation
Health & Life Sciences
Pharmaceutical
Health & Life Sciences
MedTech
Health & Life Sciences
BioTech
MedTech Valuation Multiples — FAQ
What is the average valuation multiple for MedTech companies?
As of 31 March 2025, the MedTech sector benchmark was an EV/Sales multiple of about 3.5× and an EV/EBITDA multiple of about 19.1× (median across six regions). Multiples vary by funding stage and region; stage-level and current-quarter figures are available in DealMatrix.
What is the difference between EV/Sales and EV/EBITDA for MedTech?
EV/Sales (enterprise value ÷ revenue) is used for high-growth MedTech companies that are not yet profitable, while EV/EBITDA (enterprise value ÷ operating profit) applies to mature, profitable ones. Early-stage companies are usually benchmarked on EV/Sales.
How are MedTech valuation multiples calculated?
Each MedTech multiple is a weighted blend of public-market index comparables, cleaned for outliers and gaps, then adjusted for macroeconomic conditions, region, and funding stage through a six-step model that follows the IPEV Guidelines 2025.
Do MedTech valuation multiples vary by region?
Yes. North America serves as the reference market and typically carries the highest multiples, while emerging markets trade at a structural discount. Region-specific figures are available in the DealMatrix platform.
How current is this MedTech data and how often is it updated?
The benchmark shown is an illustrative annual figure as of 31 March 2025. The underlying model is updated every quarter. Because the IPEV Guidelines 2025 prohibit static multiples for reporting periods from 1 April 2026, current quarterly data for valuations is available in the DealMatrix platform.